Acumen Research and Consulting, a global provider of market research studies, in a recently published report titled “Sickle Cell Anemia Testing & Screening Market– Global Industry Analysis, Market Size, Opportunities and Forecast, 2021-2028”
The global Sickle cell anemia testing & screening market size is projected to reach US$ 377.9 Mn by 2028, with a CAGR of 6.2% during 2021-2028
Sickle cell anemia is a hereditary red blood cell disease that doesn’t hold oxygen in the body, as a balanced red blood cell condition. The versatile, circular red cells normally pass into the blood vessels quickly. A special type of blood test is the best way to decide whether a person has sickle cell disorder, a sickle cell mutation, and other rare hemoglobinopathies.
Download Sample Pages Of This Study@ https://www.acumenresearchandconsulting.com/request-sample/2158
The growing understanding of early disease detection and treatment, the demand for sickle cell testing is projected to expand. While competition is growing and genetic screening conditions are increasing, the need for sickle cell testing is expected to expand in the next few years. Many health institutions in different countries fund the screening and treatment of fetal disease through sickle cell research. The knowledge of life-threatening sickle cell disease between parents, however, is expected to provide industry players with stronger incentives to create new drugs for sickle cell research.
SCD is a widely overlooked global health issue, especially in emerging regions that are experiencing higher disease occurrence due to a lack of understanding between patients/public and health policy makers working in these areas locally.
Public programs to help the treatment are projected to significantly fuel business demand. For starters, the National Institutes of Health (NIH) introduced in March 2020 a US$ 1 Mn technology acceleration challenge in support of the creation of effective diagnostic points of treatment. The goal is directed towards infectious illnesses, such as malaria, sickle cell disease, and anemia.
View Table Of Content Of This Study@ https://www.acumenresearchandconsulting.com/sickle-cell-anemia-testing-and-screening-market
Newborn screening services have been pilot-scale in a number of anemia-affected sickle cell countries including Ghana, Kenya, the DRC, and Benin. Successful management of this disease has pushed developed nations to adopt newborn initiatives to further promote demand development in these countries.
In order to better address challenges in conjunction with active sickle cell identification and care management, the advancement of non-invasive, portable, and emerging tools to make SCD detection simpler. Today’s developed POC instruments are focused on methods including densitometry, lateral immunoassay flow, and microfluidic electrophoresis.
Industries concentrate on the production of compact, accessible, highly responsive, and accurate point-of-care tests for HbC, HbA, and HbS. Newborn/neonatal research prioritization is required to lead to the effective production and implementation of new diagnosis and clinical treatments in sickle-cell disease.
Regional Stance
North America accounted for much of the global sickle cell anemia testing & screening market in 2019, thanks to the large number of rolled-out newborn screening services, which has provided a favorable climate for key players in the industry. The demand for sickle cell research will be affected by the understanding of sickle cell diseases. America is anticipated to be the controlled sickle cell research area, followed by France and the United Kingdom. It can be attributed to the lack of premium products, high medication expense, higher use of sickle cell test tests and the prevalence of Afro-American communities. The sickle cell test market is projected to rise fastest due to high prevalence of disease in Asia-Pacific and African countries.
Browse Upcoming Market Research Study@ https://www.acumenresearchandconsulting.com/forthcoming-reports
Key Players & Strategies
Participants include major global Quest Diagnostics, BioMedomics Inc., STRECK, Silver Lake Research Corporation, Laboratory Corporation of America Holdings, PerkinElmer Inc., HEMEX HEALTH, Bio-Rad Laboratories, and Others.
The market is highly competitive, with major players in the industry seeking to preserve market competitiveness through alliances, acquisitions and extends their company through newborn research markets. In comparison, new firms investigate the ability of point-of-care testing to maintain a strategic advantage on the market. Significant improvements in the use of HB electrophoresis and HPLC by government-initiated newborn screening and evaluation schemes have resulted in strong market penetration. That, in effect, has drawn the interest of corporations who want to change their current product line and further improve usage.
Browse All Latest Healthcare and Pharmaceuticals Reports Study@ https://www.acumenresearchandconsulting.com/industry-categories/healthcare-and-pharmaceuticals
Inquiry Before Buying@ https://www.acumenresearchandconsulting.com/inquiry-before-buying/2158
Download This Premium Research Study – https://www.acumenresearchandconsulting.com/buy-now/0/2158
Would like to place an order or any question, please feel free to contact at sales@acumenresearchandconsulting.com | +1 407 915 4157
About Us:
Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact-based decisions on technology purchases and develop firm growth strategies to sustain market competition. With a team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.